Latest news


Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital

Posted on Sep 6, 2017

Oslo (Norway), 5 September 2017 – Exercise of employee share options, mandatory notification of trade and resolution to increase the share capital in PCI Biotech Holding ASA (the “Company”).  1.   Options exercised and mandatory notification of trade Participants in the Company’s share option program have on September 5th 2017 exercised a total number of 86,500 […]

First half year 2017 report and presentation

Posted on Aug 29, 2017

Oslo, 29 August 2017 – Please find enclosed the financial report and presentation for second quarter and first half year 2017. PCI Biotech Q2 2017 Report           PCI Biotech Q2 2017 Presentation PCI Biotech reported important progress for the fimaCHEM programme during 1H 2017, with early promising signs of effect in Phase I. The study has […]

PCI Biotech appoints Dr Hans Olivecrona as Chief Medical Officer

Posted on Aug 23, 2017

Oslo (Norway), 23 August 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company is pleased to announce the appointment of Dr. Hans Olivecrona MD PhD as Chief Medical Officer (CMO). Dr Olivecrona will also serve as a member of PCI Biotech’s executive management team. He will lead the execution of all clinical development […]